Preoperative pyuria predicts the presence of high-grade bladder carcinoma in patients with bladder tumors.
bladder cancer
pyuria
transurethral resection
Journal
Central European journal of urology
ISSN: 2080-4806
Titre abrégé: Cent European J Urol
Pays: Poland
ID NLM: 101587101
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
10
2020
revised:
16
11
2020
accepted:
16
11
2020
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
ppublish
Résumé
Preoperative identification of high-grade bladder cancer presence can optimize patient management. The aim of this study was to assess the association between preoperative pyuria and the pathological features of bladder cancer. This retrospective analysis enrolled 943 patients undergoing transurethral resection of a bladder tumor. Patients were divided into two study groups based on the presence of pyuria in preoperative urine analysis, defined as the presence of >5 leukocytes in the high power field. Pyuria status as a potential predictive factor was then confronted with pathological features based on standard microscopic examination of the surgical specimen. Among 943 recruited patients, 294 (31.2%) presented with pyuria. Patients with pyuria were older (71 vs. 68 years, p <0.05), had higher rates of large (≥3 cm) tumors (37% vs. 26%, p <0.05), and more frequently presented concomitant hematuria (58% vs. 24%, p <0.05). In case of recurrent tumors patients with pyuria more often received intravesical chemotherapy in the past (4.8% vs. 1.4%, p <0.05). Regarding oncological data, patients with pyuria had significantly higher tumor stage and grade. On multivariable analysis pyuria was independently associated with high-grade tumors (OR 1.97, 95% CI 1.45-2.67). Specificity and negative predictive value of pyuria as a biomarker of high-grade tumors were 76% and 68%, respectively. Preoperative pyuria can be regarded as a predictor of the presence of high-grade bladder carcinoma in patients with bladder tumors.
Identifiants
pubmed: 33552566
doi: 10.5173/ceju.2020.0289
pii: 0289
pmc: PMC7848834
doi:
Types de publication
Journal Article
Langues
eng
Pagination
423-436Informations de copyright
Copyright by Polish Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Neoplasma. 2016;63(4):642-7
pubmed: 27268930
Eur Urol. 2015 Jan;67(1):74-82
pubmed: 25043942
Eur Urol Oncol. 2018 Oct;1(5):403-410
pubmed: 31158079
BMC Urol. 2018 Oct 22;18(1):90
pubmed: 30348146
Investig Clin Urol. 2020 Jan;61(1):51-58
pubmed: 31942463
Int J Urol. 2015 Jul;22(7):650
pubmed: 25941035
Int J Urol. 2015 Jul;22(7):645-9
pubmed: 25912166
Eur Urol Oncol. 2020 Jun;3(3):306-315
pubmed: 32199915
Urol Oncol. 2016 Nov;34(11):483.e17-483.e24
pubmed: 27646875
Cent European J Urol. 2017;70(1):22-26
pubmed: 28461983
Int Urol Nephrol. 2019 May;51(5):831-838
pubmed: 30937606
Eur Urol. 2016 Feb;69(2):231-44
pubmed: 26091833
Urol Oncol. 2018 Sep;36(9):389-399
pubmed: 29884342
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
Investig Clin Urol. 2018 Jan;59(1):10-17
pubmed: 29333509
Clin Genitourin Cancer. 2020 Apr;18(2):e167-e173
pubmed: 31635939
Int J Urol. 2009 Mar;16(3):293-8
pubmed: 19207607
Int Braz J Urol. 2019 Mar-Apr;45(2):315-324
pubmed: 30785697
Clin Genitourin Cancer. 2013 Sep;11(3):331-6
pubmed: 23664207
Arch Esp Urol. 2014 Apr;67(3):243-8
pubmed: 24840589
Arch Med Sci. 2019 Oct 07;16(4):863-870
pubmed: 32542089
Mol Clin Oncol. 2015 Sep;3(5):1113-1116
pubmed: 26623061
Eur Urol. 2015 Aug;68(2):238-53
pubmed: 25709027
Cent European J Urol. 2017;70(1):27-28
pubmed: 28466880
Cancer Res. 1995 Aug 1;55(15):3438-43
pubmed: 7542171
Eur J Cancer Care (Engl). 2017 Mar;26(2):
pubmed: 26714143
Front Oncol. 2019 Jan 17;8:642
pubmed: 30705874
Int J Urol. 2020 Nov;27(11):1024-1030
pubmed: 32875619